Lazard Asset Management LLC Sells 143,847 Shares of Danaher Corporation $DHR

Lazard Asset Management LLC lowered its holdings in shares of Danaher Corporation (NYSE:DHR) by 6.6% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,028,965 shares of the conglomerate’s stock after selling 143,847 shares during the period. Lazard Asset Management LLC’s holdings in Danaher were worth $384,692,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of DHR. Sivia Capital Partners LLC raised its stake in Danaher by 6.3% during the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after acquiring an additional 119 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Danaher by 34.5% during the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after purchasing an additional 14,217 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Danaher by 40.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock worth $610,000 after purchasing an additional 886 shares in the last quarter. Ieq Capital LLC lifted its stake in Danaher by 64.2% in the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after purchasing an additional 29,592 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its stake in Danaher by 30.7% in the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock valued at $273,000 after purchasing an additional 325 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Analyst Ratings Changes

DHR has been the topic of a number of research reports. TD Cowen decreased their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. cut their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Citigroup assumed coverage on Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective on the stock. Evercore reaffirmed an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Finally, Morgan Stanley dropped their target price on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Price Performance

Shares of NYSE:DHR opened at $191.87 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm has a market cap of $134.88 billion, a PE ratio of 34.08, a price-to-earnings-growth ratio of 2.38 and a beta of 0.79. The firm’s fifty day moving average is $185.64 and its 200-day moving average is $196.76.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the company earned $0.77 EPS. Sell-side analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. Danaher’s dividend payout ratio is presently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.